Meeting
2022 ASCO Annual Meeting
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma.
Authors
Masamichi Takahashi
Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan
Masamichi Takahashi , Satoshi Kawashima , Yohei Otake , Natsuko Satomi-Tsushita , Aya Kuchiba , Ryo Sadachi , Keiko Ohata , Hitoshi Ozawa , Kan Yonemori , Motoo Nagane , Yoshiki Arakawa , Akitake Mukasa , Shota Tanaka , Ryo Nishikawa , Yoshihiro Muragaki , Kenkichi Masutomi , Koichi Ichimura , Kenichi Nakamura , Yoshitaka Narita
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
UMIN000030359
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2036)
DOI
10.1200/JCO.2022.40.16_suppl.2036
Abstract #
2036
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
First Author: Manmeet Singh Ahluwalia
Poster
2021 ASCO Annual Meeting
Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.
First Author: Jian Li Campian
Poster
2020 ASCO Virtual Scientific Program
Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial.
First Author: Jaleh Fallah
Poster
2016 ASCO Annual Meeting
A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma.
First Author: Manmeet Singh Ahluwalia